Eversense is a CGM that goes under the skin and stays there for up to six months. The company that makes it has big plans to make that time period longer and to make the sensor even more accurate.
Stacey talks to Senseonics Chief Medical Officer Dr. Francine Kaufman. They had a wide ranging conversation about everything from sensor length to interoperability and working with different pump systems as well as access and so much more. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider.
Check out Stacey's book: The World's Worst Diabetes Mom!
Join the Diabetes Connections Facebook Group!
Sign up for our newsletter here
Episode Transcription Below (or coming soon!)
Please visit our Sponsors & Partners - they help make the show possible!
It's in the News.. the top diabetes stories of the past seven days. This week, one state caps not just insulin prices, but diabetes supplies for some, Lilly is out with a new integrated pen system, new study look at DKA at diagnosis of type 1 and what that means for health issues later on, and more!
Learn more about the T1D Exchange: www.t1dexchange.org/stacey
Check out Stacey's book: The World's Worst Diabetes Mom!
Join the Diabetes Connections Facebook Group!
Sign up for our newsletter here
Episode Transcription Below (or coming soon!)
Please visit our Sponsors & Partners - they help make the show possible!
Hello and welcome to Diabetes Connections In the News! I’m Stacey Simms and these are the top diabetes stories and headlines of the past seven days.
XX
In the news is brought to you by T1D Exchange! T1D Exchange is a nonprofit organization dedicated to improving outcomes for the entire T1D population.
https://t1dexchange.org/stacey/
XX
And by my new book “Still The World's Worst Diabetes Mom: More Real Life Stories of Parenting a Child With Type 1 Diabetes” available on Amazon now.
XX
Delaware Governor John Carney last month signed Senate Bill 316, which will cap the monthly cost of diabetes supplies and equipment at $35 for those on state insurance plans. This law will make blood glucose meters and strips, urine testing strips, syringes, continuous glucose monitors (CGM) and supplies, and insulin pump, and pump supplies more affordable and accessible.
Senate Bill 316 will apply to state-regulated health plans and state employee plans, which will take effect in 2023 and 2024, respectively. The $35 per month cap includes deductible payments and cost-sharing amounts charged once a deductible is met. The cap does not, however, apply to high deductible health plans or catastrophic health plans.
Although much of the conversation about diabetes costs focuses on insulin, diabetes supplies are also a significant cost for people with diabetes. According to the American Diabetes Association (ADA), people with diabetes have medical expenses of about 2.3 times higher than those without diabetes.
Diabetes supplies account for about 15 percent of diabetes medical expenses. On average, people with diabetes, even those with private insurance, spend $490 out-of-pocket on diabetes-related supplies each year.
https://diatribe.org/delaware-caps-monthly-cost-diabetes-supplies-35
XX
New report estimates 1 point 3 million adults with diabetes have rationed their use of insulin within the last year. That’s 16.5 percent of everyone who’s been prescribed insulin. We told you about this report published last month in the journal Annals of Internal Medicine. It’s getting more attention – and it should – as the Washington Post picked it up for a series of reports their doing on health stats. The report attributes the rationing to the cost of the drug and what it describes as “inadequate” insurance coverage. The price of the four most popular types of insulin has tripled in the past decade, according to the American Diabetes Association.
https://www.washingtonpost.com/wellness/2022/11/08/diabetes-insulin-rationing/
XX
One of the insulin makers will begin rolling out a new diabetes management platform in the next few weeks. Lilly is launching the Tempo platform, which includes prefilled, disposable Tempo Pens for insulin delivery with the compatible TempoSmart mobile app and the Tempo Smart Button, which is designed to track the pens’ insulin dosages.The Tempo Smart Button was cleared by the FDA in mid-September, Lilly said in this week’s announcement. When attached to the top of a Tempo insulin pen, it takes in and stores insulin dosing data, then automatically transfers that information to the TempoSmart app.
TempoSmart can connect to a variety of other devices and apps, like Dexcom’s continuous glucose monitors and Lilly’s own blood glucose monitor, among others, but also from more general health-tracking wearables like those from Fitbit, Garmin, Google and Apple.
https://www.fiercebiotech.com/medtech/eli-lilly-lines-launch-diabetes-management-platform-tracks-insulin-pen-use-blood-sugar
XX
XX
New research at Georgia Tech shows promise in beta cell transplantation without having to take additional immunosuppressive drugs. This is cell therapy with a new biomaterial called iTol-100. That’s the basis of a new startup called iTolerance. Long way to go here but a lot of promise for many other conditions as well at type 1. This is less cell encapsulation, as other companies are working toward, but it’s more of a soft material that can mix right with the cells at the time of transplant. This research started with a three year grant from JDRF.
https://www.research.gatech.edu/new-startup-develops-potential-cure-type-1-diabetes
XX
Not a big surprise, but children diagnosed while in DKA can increase the risk of health issues later on. These issues can include extended stays in hospital, poorer long-term control of blood sugar levels, and even a higher mortality rate.
The authors of the study point out that providing a comprehensive explanation of the classic symptoms of T1D in childhood to the general public, those active in the childcare or daycare settings, and primary care physicians could help raise awareness of the symptoms of T1D. Furthermore, public health measures could be used, e.g., implementing a general islet-cell autoantibodies screening program for children to reduce the number of dangerous metabolic imbalances.
https://www.news-medical.net/news/20221108/Study-highlights-the-need-for-early-and-timely-diagnosis-of-type-1-diabetes-in-children-and-adolescents.aspx
XX
New weekly injection for type 2 had some promising results, helping people meet blood glucose goals 4-12 weeks earlier than those taking traditional medications. The new medication is called Tirzepatide brand name Mounjaro, and it helped people meet weight loss and blood glucose targets four weeks sooner than semaglutide, which is branded as Ozempic or Wegovy and between four and 12 weeks thatn those treated with once daily long acting insulin like Tresiba.
https://scitechdaily.com/a-new-and-improved-diabetes-drug/
XX
Quick clarification from last week! I mentioned a study showing that people with type 1 see good results from taking GLP-1 receptor agonists and SGLT 2 inhibitors, two types of drugs approved for type 2. I had said that both also increased the risk of DKA. That’s not true.. I got it wrong. Only SGLT 2 inhibitors seem to increase that risk. The GLP-1 medicines have brand names like Ozempic or Trulicity and the SGLT-2 are Invokana or Jardiance.
https://www.medwirenews.com/diabetes/real-world-adjunctive-medication-outcomes-type-1-diabetes/23662504
XX
XX
XX
Back to the news in a moment but first..
The T1D Exchange Registry is a research study conducted online over time, designed to foster innovation and improve the lives of people with T1D. The platform is open to both adults and children with T1D living in the U.S. Personal information remains confidential and participation is fully voluntary. Once enrolled, participants will complete annual surveys and have the opportunity to sign up for other studies on specific topics related to T1D. The registry aims to improve knowledge of T1D, accelerate the discovery and development of new treatments and technologies, and generate evidence to support policy or insurance changes that help the T1D community. By sharing opinions, experiences and data, patients can help advance meaningful T1D treatment, care and policy.
The registry is now available on the T1D Exchange website and is simple to navigate, mobile and user-friendly. For more information or to register, go to www.t1dregistry.org/stacey
XX
XX
XX
On the podcast next week.. Tom from Type One Talks
The past episode was all about thinking through your use of CGM, questions to ask of yourself, your family and anyone with whom you plan to share.
Listen wherever you get your podcasts
That’s In the News for this week.. if you like it, please share it! Thanks for joining me! See you back here soon.
Type One Talks is a popular YouTube channel with videos that help manage all sort of technology and situations around diabetes. But its host and founder says he wasn’t always that interested a diabetes deep dive. It all changed with his first CGM. Tom was an accountant in his former life so he really does love numbers. We’ll talk about his diagnosis as a child in the former Czechoslovakia, how much everything has changed and why he started making videos about diabetes technology, basically experimenting on himself.
This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider.
Check out Stacey's book: The World's Worst Diabetes Mom!
Join the Diabetes Connections Facebook Group!
Sign up for our newsletter here
Episode Transcription Below (or coming soon!)
Please visit our Sponsors & Partners - they help make the show possible!
It's in the News.. the top diabetes stories of the past seven days. This week: new research looks at off-label use of GLP and SGLT drugs for people with type 1, Medtronic gets 780G approval in Canada, finger prick early detection of type 1, and lots going on for Diabetes Awareness Month.
Check out Stacey's book: The World's Worst Diabetes Mom!
Join the Diabetes Connections Facebook Group!
Sign up for our newsletter here
Episode Transcription Below (or coming soon!)
Please visit our Sponsors & Partners - they help make the show possible!
Hello and welcome to Diabetes Connections In the News! I’m Stacey Simms and these are the top diabetes stories and headlines of the past seven days.
XX
In the news is brought to you by T1D Exchange! T1D Exchange is a nonprofit organization dedicated to improving outcomes for the entire T1D population.
https://t1dexchange.org/stacey/
XX
And by my new book “Still The World's Worst Diabetes Mom: More Real Life Stories of Parenting a Child With Type 1 Diabetes” available on Amazon now.
XX
Our top story this week,
Researchers say a blood test for early diagnosis of type 1 diabetes can stave off serious illness and hospitalization in children. This Australian study looked at the finger prick sample that is collected in the home and mailed to the lab. It included more than 17-thousand children and young adults, mostly in families with a history of type 1. The team of researchers are the first to use this method to screen diabetes in Australia. They said, We want to make type 1 diabetes screening accessible to every Australian child no matter where they live. Our recent work has proven that we can do this cheaply, accurately, and conveniently,"
The study is published in Pediatric Diabetes.
https://medicalxpress.com/news/2022-11-home-screening-diabetes.html
XX
Medtronic gets the okay from Canada for it’s MiniMed 780G system. It’s now available in more than 60 countries around the world, with the U.S. notably missing from the list. Current 770G users will be able to upgrade their devices with the new system’s software. The MiniMed 780G is equipped with Medtronic’s SmartGuard technology, a hybrid closed-loop system what works with Medronic’s CGM. It’s approved for ages 7-80. Medtnoic submitted to the FDA in the spring of 2021, nearly a year after securing CE mark approval in Europe.
The U.S. sign-off has been slow to arrive, however, thanks in large part to the FDA’s discovery of quality control issues at the California headquarters of Medtronic’s diabetes business. A December 2021 letter from the agency outlined shortfalls it discovered at the Los Angeles-area facility in a routine inspection, prompting Medtronic to implement corrective actions and other process improvements to address the issues.
https://www.fiercebiotech.com/medtech/still-awaiting-us-approval-medtronics-auto-adjusting-insulin-pump-lands-canadian-nod
XX
XX
People with type 1 diabetes who take GLP-1 receptor agonists or SGLT-2 inhibitors in real life seem to line up with controlled trials. The GLP-1 medicines have brand names like Ozempic or Trulicity and the SGLT-2 are Invokana or Jardiance. These are newer medications and people with type 1 are cautioned to take them carefully because of the higher risk of DKA. However, these researchers say after 12 months of use people taking a GLP-1 receptor agonist had a significant reduction in glycated hemoglobin (HbA1c), from an average of 7.7% to 7.3% (61 to 56 mmol/mol), as well as in bodyweight, from an average of 90.4 to 85.4 kg. and they used less insulin overall.
SGLT2 inhibitors were used by 39 study participants for an average duration of 24.2 months, mostly with the intent to achieve better glycemic control (73.3%), but also for weight loss (37.8%), reduced insulin requirements (26.7%), and reduced glucose variability (24.4%). Also, about 12% of users initiated SGLT2 inhibitors for their beneficial cardiovascular or renal properties.
In line with clinical trial findings, these real-world users had significant reductions in average HbA1c after 12 months of use, from 7.9% to 7.3% (63 to 56 mmol/mol), and in basal insulin dose, from a daily average of 31.3 to 25.6 units, but not in bolus insulin.
And contrary to the results of controlled trials, although SGLT2 inhibitor users had a weight reduction, this was small and not statistically significant, at an average of 89.2 and 87.5 kg before and after 12 months, respectively.
https://www.medwirenews.com/diabetes/real-world-adjunctive-medication-outcomes-type-1-diabetes/23662504
XX
Taking a personalized approach to kidney disease screening for people with type 1 diabetes (T1D) may reduce the time that chronic kidney disease (CKD) goes undetected. The finding, published in Diabetes Care(link is external), provides the basis for the first evidence-based kidney screening model for people with T1D.
Current CKD screening recommendations include annual urinary albumin excretion rate (AER) testing for anyone who has had T1D for at least five years. The new findings suggest that AER screening could be personalized to optimize testing frequency and early detection of CKD. Specifically, people with T1D who are at low risk of developing CKD could be tested for AER less frequently to reduce burden and cost, and those at high risk for CKD could be tested more frequently to facilitate earlier CKD detection. People with T1D have an estimated 50% risk of developing CKD over their lifetime. Important to note, these numbers and this study is based on 30 years of data, dating back to the landmark DCCT trial.
https://www.nih.gov/news-events/news-releases/nih-funded-study-finds-personalized-kidney-screening-people-type-1-diabetes-could-reduce-costs-detect-disease-earlier
XX
Lots of stuff happening for diabetes awareness month. Embecta Corp. (“embecta”) (Nasdaq: EMBC), one of the largest pure-play diabetes care companies in the world, today announced it will ring the opening bell at Nasdaq on November 1, 2022, in recognition of National Diabetes Awareness Month.
“We are proud to celebrate this year’s Diabetes Awareness Month by ringing the Nasdaq Opening Bell with representatives of several organizations that make diabetes, and supporting the people who are living with diabetes, their sole focus,” said Devdatt “Dev” Kurdikar, president and chief executive officer of embecta. “Our company is honored to recognize the patients, caregivers, healthcare providers, and advocacy organizations working together to improve access to education and progress toward the vision of a life unlimited by diabetes.”
embecta also recognizes the 100-year milestone of the first successful injection of insulin that was administered to a person with diabetes. Today, 1 in 10 adults around the world live with diabetes1, an estimated 537 million people, and almost half don’t know they have it.
“Our community often faces stigma and isolation associated with diabetes as we frequently practice self-management of the disease,” said Anna Norton, chief executive officer of DiabetesSisters. “Increased access to education and resources that will improve the standard of care and quality of life across the community is essential, and we’re proud to stand with embecta to share in this mission.”
The bell ringing ceremony will be streamed live via Nasdaq’s Facebook page. Additionally, highlights from the ceremony will be shared across embecta’s social media channels. Please visit embecta.com for additional information regarding Diabetes Awareness Month.
About embecta
embecta, formerly part of BD (Becton, Dickinson and Company), is one of the largest pure-play diabetes care companies in the world, leveraging its nearly 100-year legacy in insulin delivery to empower people with diabetes to live their best life through innovative solutions, partnerships and the passion of more than 2,000 employees around the globe. For more information, visit embecta.com.
XX
Dexcom has teamed up with ESPN’s Adam Schefter – his wife has type 1 – to launch Dexcom U, the first-ever NIL (name, image, likeness) program designed to celebrate college athletes with diabetes and inspire people with diabetes who have athletic dreams of their own. NIL is name image likeness, it’s the new program that allows college athetes to be paid. Dexcom says According to a recent study, nearly half (43%) of adults with Type 1 diabetes felt like quitting sports and physical activities because of their diagnosis, and one in five (20%) went through with quitting. These athletes tell their stories and how Dexcom helps them. I’ll link up the video and we are set to speak with some of them in the next couple of weeks.
XX
A new study released by the American Diabetes Association® (ADA), illustrates the significant barriers that low-income Americans, people of color, older Americans, and people with diabetes living in states with the highest prevalence of the disease face in accessing continuous glucose monitors (CGM). These barriers are especially high for Americans on Medicaid, who are the least likely to have access to a CGM. CGMs continually monitor blood glucose (blood sugar), giving real-time updates. The devices provide significant, potentially life-changing benefits for diabetes management, and in turn for the avoidance or delay of serious co-morbidities, hospitalizations, and even death.
“It is disappointing to see that access to vital diabetes management tools like CGMs often depends on your income, the color of your skin, your age, and where you live,” said Dr. Robert Gabbay, chief scientific and medical officer at the ADA. "The ADA is committed to addressing access barriers—such as inadequate health insurance coverage, steep Medicare and Medicaid coverage requirements, and physician shortages—to ensure that everyone who can benefit from a CGM can get one.”
The ADA is working with the Centers for Medicare and Medicaid Services, state Medicaid programs, and Congress to eliminate barriers people face in accessing diabetes technology like CGMs. The CGM study is available on the ADA’s website.
XX
Diabetes on Nasdaq
XX
Great start to a blog post by Tim Street, he writes over at DiabeticTech. He’s trying out 6 CGMs currently on the market.
Dexcom ONE
Medtrum Nano
Dexcom G6
Glucomen Day
GlucoRX Aidex
Freestyle Libre2
You can check out his blog to see the photos of him wearing all of the CGMs and hear his methods for testing.
https://www.diabettech.com/cgm/unboxing-and-applying-the-six-cgms/?utm_source=dlvr.it&utm_medium=facebook
XX
Dexcom also has a See Diabetes campaign for this month which gives you a chance to create your own overlay patch. I’ve created one for the show, you can it on social along with others with the #SeeDiabetes hashtag. Patti LaBelle, Mark Andrews and Nick Jonas are taking part.. If you design an overlay – I’ll put the link in the show notes – you may be order a few for free – they’re saying limited supply. A cynic would say this is a creative way to use up the G6 overlay patches before the G7 comes out but.. personally I think it’s a really creative and fun idea. I like how mu patch came out, but I doubt my son will wear it!
XX
Back to the news in a moment but first..
The T1D Exchange Registry is a research study conducted online over time, designed to foster innovation and improve the lives of people with T1D. The platform is open to both adults and children with T1D living in the U.S. Personal information remains confidential and participation is fully voluntary. Once enrolled, participants will complete annual surveys and have the opportunity to sign up for other studies on specific topics related to T1D. The registry aims to improve knowledge of T1D, accelerate the discovery and development of new treatments and technologies, and generate evidence to support policy or insurance changes that help the T1D community. By sharing opinions, experiences and data, patients can help advance meaningful T1D treatment, care and policy.
The registry is now available on the T1D Exchange website and is simple to navigate, mobile and user-friendly. For more information or to register, go to www.t1dregistry.org/stacey
XX
XX
XX
On the podcast next week.. Tom from Type One Talks
The past episode was all about thinking through your use of CGM, questions to ask of yourself, your family and anyone with whom you plan to share.
Listen wherever you get your podcasts
That’s In the News for this week.. if you like it, please share it! Thanks for joining me! See you back here soon.
When it comes to using a CGM, the first question you may ask is, "How quickly can I get one?!" But this week, you'll hear there are a few other questions you may want to ask in order to get the most out of continuous glucose monitoring.
In this excerpt from "Still the World's Worst Diabetes Mom: More Real Life Stories of Parenting a Child With Type 1 Diabetes," Stacey lays out conversations to have BEFORE you decide whether and how to use a CGM. Thinking this out can make your child’s use of a CGM more effective and with less stress for you. It may even be helpful for adults considering sharing their CGM information.
Stacey's new book is now available on Amazon, Target wherever you get books online. The audiobook will be out in a few weeks.
Check out Stacey's books: The World's Worst Diabetes Mom & Still The World's Worst Diabetes Mom!
Join the Diabetes Connections Facebook Group!
Sign up for our newsletter here
Episode Transcription Below (or coming soon!)
Please visit our Sponsors & Partners - they help make the show possible!
The author of Six Until Me, Kerri Sparling, isn’t blogging any more, but she’s still looking for stories of connection and community built around conversation
For 14 years Kerri wrote a daily blog about her experience with type 1. She put aside SixUntilMe in 2019. We’re going to talk about her new book, what she thinks about the online community these days and what’s next.
This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider.
Check out Stacey's book: The World's Worst Diabetes Mom!
Join the Diabetes Connections Facebook Group!
Sign up for our newsletter here
Episode Transcription Below (or coming soon!)
Please visit our Sponsors & Partners - they help make the show possible!
It’s It’s “In the News…” a look at the top diabetes stories and headlines of the past seven days. This week: a troubling new study about how many people with diabetes ration insulin, a new study looks at OpenAPS compared to traditional pumps, more research on Beta Bionics' iLet pump, an old diabetes drug might help in the fight against dementia, and more!
Learn more about the T1D Exchange: https://t1dexchange.org/stacey/
Check out Stacey's book: The World's Worst Diabetes Mom!
Join the Diabetes Connections Facebook Group!
Sign up for our newsletter here
Episode Transcription Below (or coming soon!)
Please visit our Sponsors & Partners - they help make the show possible!
Hello and welcome to Diabetes Connections In the News! I’m Stacey Simms and these are the top diabetes stories and headlines of the past seven days.
XX
In the news is brought to you by T1D Exchange! T1D Exchange is a nonprofit organization dedicated to improving outcomes for the entire T1D population.
https://t1dexchange.org/stacey/
XX
A new study shows nearly 1 in 5 adults in the U.S. with diabetes either skipped, delayed or used less insulin than was needed to save money. That comes out to roughly 1.3 million adults, or 16.5% of those who need insulin. The findings were based on data from the 2021 National Health Interview Survey, which is conducted annually by the Centers for Disease Control and Prevention and which interviews tens of thousands of Americans about their health-related experiences. It was the first time that the CDC had included questions about insulin use, though concerns about sky-high insulin prices have been reported for years.
Starting Jan. 1, the Inflation Reduction Act, signed into law by President Joe Biden in August, will cap the monthly cost of insulin at $35 for seniors on Medicare. The bill, however, will leave out millions of Americans with private health insurance as well as those who are uninsured. It was also found to be more common among people with type 1 diabetes, at 18.6%, compared to those with type 2 diabetes, at 15.8%
https://www.nbcnews.com/health/health-news/insulin-prices-many-adults-diabetes-ration-insulin-study-finds-rcna52287?cid=sm_npd_nn_tw_ma
XX
New islet cell transplant study looks very promising. Long term outcomes of two phase 3 clinical trials shows many patients didn’t need insulin to maintain their blood sugar for up to eight years. It also showed that a new approach required fewer transplants than typical and was exceedingly safe. These trials included people who had kidney transplants and showed islet cell transplants for those people was safe and effective.
75 percent who initially were able to come off insulin therapy, more than half maintained total insulin independence, meaning they needed no additional insulin injections throughout the years of follow-up.
https://www.pennmedicine.org/news/news-releases/2022/october/new-islet-transplant-method-leads-to-insulin-independence
XX
Study out of New Zealand looked at DIY diabetes tech and compared to some commercial offerings. Not sure what they were tyring to prvoe here because they looked at a closed loop system OpenAPS and compared it to a regular old pump and CGM system with no automation. No surprisingly, the people with type 1 in the AID group had much more time in range – about 14 percent more – than those using a standalone pump and CGM. No severe lows or DKA in either group. But these days, IMO, looking at an automated insulin delivery system to a pump and CGM that don’t communicate is like comparing apples and chain saws.
https://www.medtechdive.com/news/do-it-yourself-artificial-pancreas-diabetes/633888/
XX
More good news for the iLet Bionic Pancreas. A clinical trial, conducted at 16 clinical sites across the United States, enrolled 326 participants ages 6 to 79 years who had type 1 diabetes and had been using insulin for at least 1 year.
Participants were randomly allocated to a treatment group using the bionic pancreas or a standard-of-care control group that continued with their pre-trial method of glucose monitoring and insulin dosing.
In participants using the bionic pancreas, A1C improved from 7.9% to 7.3%, yet remained unchanged among the control group. The iLet doesn’t use carb counting – just meal announcements and it sets basal rates with just the user’s body weight. It’s currently in front of the US FDA, awaiting approval.
XX
Insulet issued an urgent medical device correction on Monday related to battery problems with a component of its Omnipod DASH system.
The device uses a wearable insulin pod that’s controlled by a personal diabetes manager (PDM), a smartphone-like device that does the calculations for bolus insulin doses.
Insulet plans to replace the PDMs for all of its current Omnipod DASH users globally, incurring an aggregate charge of $35 million to $45 million, J.P. Morgan Analyst Robbie Marcus wrote in a Monday research note.
Insulet said it received reports of some Omnipod DASH users having battery problems with their PDM devices, including the battery swelling, fluid leaking from the battery, and in rare cases, extreme overheating. In a letter to users, the company said it plans to ship updated devices to all current Omnipod DASH customers in the coming months.
The battery issue applies to all of Insulet’s Omnipod DASH PDMs, but the likelihood of problems may increase if the device has been in use longer than 18 months. Charging the device to a full battery and leaving it on the charger overnight also increases the risk.
So far, Insulet said it has not received reports of any injuries related to the battery issues.
The company advised patients to monitor their PDMs for battery problems, including a bulging back cover and the device losing its charge very quickly, overheating or emitting an odor.
If patients notice any of these problems, they should not charge the device, stop using the system and switch to a backup insulin plan as soon as they can. Users can also contact Insulet for a temporary replacement device.
https://www.medtechdive.com/news/insulet-battery-problems-omnipod-dash/634275/
XX
MDT) announced today that it introduced a new diabetes management program for users of the MiniMed 770G insulin pump.
The medtech giant calls the new program My Insights. It designed it exclusively for individuals using the MiniMed 770G hybrid closed-loop insulin delivery system.
Using an individual’s data, My Insight provides personalized tips, trends and reminders to help customers manage their diabetes. Its personalized recommendations come through via monthly emails with educational content. Medtronic aims to make the content relevant based on what the individual experiences.
Medtronic said it represents the first diabetes management program to go beyond “generalized tips.” Instead, it offers personalized suggestions using data from the integrated insulin pump system.
The company said it made My Insights available in the U.S. to anyone using MiniMed 770G.
https://www.drugdeliverybusiness.com/medtronic-launches-diabetes-insights-program-for-minimed-users/
XX
Some countries are seeing shortages of Ozempic, a weekly injectable meant for people with diabetes but can be prescribe off label for weight loss. Demand has gone way up since some Tik Tok and social media influencers have shared Ozempic as a weight loss drug. Diabetes groups and especially Australian advocacy groups have advised doctors to limit prescribing the drug to people with Type 2 diabetes.
https://www.abc.net.au/news/2022-10-17/ozempic-weight-loss-demand-type-2-diabetes-drug-shortage/101542226
XX
Back to the news in a moment but first..
The T1D Exchange Registry is a research study conducted online over time, designed to foster innovation and improve the lives of people with T1D. The platform is open to both adults and children with T1D living in the U.S. Personal information remains confidential and participation is fully voluntary. Once enrolled, participants will complete annual surveys and have the opportunity to sign up for other studies on specific topics related to T1D. The registry aims to improve knowledge of T1D, accelerate the discovery and development of new treatments and technologies, and generate evidence to support policy or insurance changes that help the T1D community. By sharing opinions, experiences and data, patients can help advance meaningful T1D treatment, care and policy.
The registry is now available on the T1D Exchange website and is simple to navigate, mobile and user-friendly. For more information or to register, go to www.t1dregistry.org/stacey
XX
XX
XX
New research shows an older drug for type 2 might help reduce the risk for dementia. People with diabetes are at higher risk of developing dementia. These researchers looked though 500-hundred thousand past medical records and found that an older class of type 2 diabetes medication known as glitazones helps reduce a person’s dementia risk by 22%. These reerahres say its very promising but they want to see more real world study and also combine glitazones with other types of treatments
https://www.medicalnewstoday.com/articles/type-2-diabetes-drug-may-help-lower-dementia-risk-by-22
XX
On the podcast next week.. Kerri Sparling from SixUntilMe
The past episode was all about teens and type 1 – a deep dive into why teen retreats work from the people who organize a great one.. and how adults with type 1 still use the lessons they learned as teens.
Listen wherever you get your podcasts
That’s In the News for this week.. if you like it, please share it! Thanks for joining me! See you back here soon.
Who would volunteer to spend a weekend with a bunch of teens with type 1? A bunch of people who’ve been there! We’re talking about teen retreats – and what even adults can learn – about the power of connection.
Patrick Mertes has lived with type 1 since he was a child. If that name sounds remember, he’s one of the climbers from the 50-in-50 project where he and a friend climbed the highest peak in all 50 states in 50 days a couple of years back. He also runs a fantastic family and teen retreat in North Carolina.
This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider.
Check out Stacey's book: The World's Worst Diabetes Mom!
Join the Diabetes Connections Facebook Group!
Sign up for our newsletter here
Episode Transcription Below (or coming soon!)
Please visit our Sponsors & Partners - they help make the show possible!
It's It’s “In the News…” a look at the top diabetes stories and headlines of the past seven days. This week: Provention Bio hopes to get FDA approval of Teplizumab next month and partners with Sanofi on this T1D prevention drug, new type 2 studies show that younger people who develop it generally have worse health outcomes, Medicare considers expanded coverage of CGMs and more
Learn more about the T1D Exchange: www.T1Dexchange.org/Stacey
Check out Stacey's book: The World's Worst Diabetes Mom!
Join the Diabetes Connections Facebook Group!
Sign up for our newsletter here
Episode Transcription Below (or coming soon!)
Please visit our Sponsors & Partners - they help make the show possible!
Hello and welcome to Diabetes Connections In the News! I’m Stacey Simms and these are the top diabetes stories and headlines of the past seven days.
XX
In the news is brought to you by T1D Exchange! T1D Exchange is a nonprofit organization dedicated to improving outcomes for the entire T1D population.
https://t1dexchange.org/stacey/
XX
Provention Bio partners with Sanofi to help bring teplizumab to market. Teplizumab isn’t yet approved, the FDA is expected to give it the thumbs up later this year.. this is the drug shown to prevent type 1 diabetes for up to three years. Among other things, Sanofi will get exclusive global marketing rights for the drug. The FDA had asked for more information the last time teplizumab was up for approval.. the three month period for that closes in November.. and a ruling is expected then.
https://www.fiercepharma.com/pharma/proventions-regulatory-odyssey-diabetes-nears-its-end-company-taps-sanofi-marketing-assist
XX
New research has found that the age at which people are diagnosed with type 2 diabetes is associated with a higher risk of developing serious complications.
The study, which was published in JAMA Network Open, analyzed health data from more than 36,000 Americans aged 50 and above.
The researchers found that those who were diagnosed with type 2 diabetes between the ages of 50 and 59 had “elevated risks” of heart disease, stroke, disability, cognitive impairment, and early death. But when people were diagnosed with diabetes later in life, the risks were reduced.1 No obvious reason for that.. but the researchers say it does point to the need for more screening and better prevention and treatment.
https://www.verywellhealth.com/type-2-diabetes-diagnosis-age-6747897
XX
The Centers for Medicare and Medicaid Services has proposed new draft coverage guidelines for continuous glucose monitors.
Under the proposal, the CMS would cover CGMs for diabetes patients who are treated with insulin or “have a history of problematic hypoglycemia,” as defined by the frequency or severity of low blood sugar events, seemingly regardless of whether they have Type 1 or 2 diabetes.
Analysts at J.P. Morgan said the proposal reads “very favorably” for Abbott and Dexcom, leading CGM manufacturers that are targeting the “massive and highly under-penetrated Type 2 market opportunity.”
https://www.medtechdive.com/news/dexcom-abbot-CGM-diabetes-coverage/633577/
XX
Mark cuban’s Cost Plus Drugs has joined with
@RocheDiabetesUS
to provide our patients with their line of Accu-ChekⓇ test strips, lancets, & meters!
This partnership will allow anyone to access what they need to check their blood sugar, at a low price.
XX
Researchers who study Type 2 diabetes have reached a stark conclusion: There is no device, no drug powerful enough to counter the effects of poverty, pollution, stress, a broken food system, cities that are hard to navigate on foot and inequitable access to health care, particularly in minority communities. This is a long and complicated article published in the New York Times.. I’ll link it up and I urge you to read it. I can’t really to it justice in a short excerpt here.
“Our entire society is perfectly designed to create Type 2 diabetes,” said Dr. Dean Schillinger, a professor of medicine at University of California, San Francisco. “We have to disrupt that.”
Dr. Schillinger and nearly two dozen other experts laid out a road-map for doing so earlier this year in a comprehensive national report to Congress on diabetes, the first of its kind since 1975.
It calls for reframing the epidemic as a social, economic and environmental problem, and offers a series of detailed fixes, ranging from improving access to healthy food and clean water to rethinking the designs of communities, housing and transportation networks.
https://www.nytimes.com/2022/10/05/health/diabetes-prevention-diet.html
XX
Back to the news in a moment but first..
The T1D Exchange Registry is a research study conducted online over time, designed to foster innovation and improve the lives of people with T1D. The platform is open to both adults and children with T1D living in the U.S. Personal information remains confidential and participation is fully voluntary. Once enrolled, participants will complete annual surveys and have the opportunity to sign up for other studies on specific topics related to T1D. The registry aims to improve knowledge of T1D, accelerate the discovery and development of new treatments and technologies, and generate evidence to support policy or insurance changes that help the T1D community. By sharing opinions, experiences and data, patients can help advance meaningful T1D treatment, care and policy.
The registry is now available on the T1D Exchange website and is simple to navigate, mobile and user-friendly. For more information or to register, go to www.t1dregistry.org/stacey
XX
The Diabetes Design initiative is looking for college age people with type 1 to help them design the ultimate alarm for an extreme low. I’ll put the contact info in the show notes, along with a link to the website. By the way, I had never heard of the Diabetes Design Initiative but boy do I know these names and you probably do too. Ben West, Dana Lewis and a few others from the history of we are not waiting
http://ddi.ucsd.edu/about.html
Grace Zheng gzheng@ucsd.edu
XX
On the podcast next week.. teens and type 1 – a deep dive into why teen retreats work from the people who organize a great one.. and how adults with type 1 still use the lessons they learned as teens.
This past episode is all about Dexcom design.
Listen wherever you get your podcasts
Hey for you parents, we’ve got a webinar on Halloween, link in the show notes and on my social media.
That’s In the News for this week.. if you like it, please share it! Thanks for joining me! See you back here soon.
We're taking a look at the design decisions that go into diabetes technology, specifically Dexcom’s G7. Beyond the accuracy and interoperability we all want, they also look at things like dexterity, feel and hand strength. Alex Diener is Dexcom’s Senior Director of Global Product Design. He lives with type 1 and he shared a lot of the behind the scenes thought process that’s gone into the design of the G7 sensor and transmitter and the apps that go along with it.
This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider.
Halloween webinar for parents: https://us02web.zoom.us/webinar/register/WN_0Xaaj9hoR-u96Kxm-OjfSQ
Moms' Night Out event: https://diabetes-connections.com/diabetes-connections-presents-moms-night-out/
Check out Stacey's books and use promo code "Spooky" to save $3!
More about Dexcom:
Our interviews with CEO Kevin Sayer: https://diabetes-connections.com/?s=sayer
Our interviews with COO Jake Leach: https://diabetes-connections.com/?s=leach
Join the Diabetes Connections Facebook Group!
Sign up for our newsletter here
Episode Transcription Below (or coming soon!)
Please visit our Sponsors & Partners - they help make the show possible!